BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Discover\, Develop and Selectively Deliver Highly Stable and P
 otent RNAi Therapeutics for Targeted and Effective Gene Silencing in Onco
 logy\, Rare\, Cardiovascular Disorders and Beyond\n\nThe 7th RNAi-Based T
 herapeutics Summit is the industry's premier dedicated forum for translat
 ing the next wave of siRNA and microRNA drugs from bench to bedside. As t
 he only event uniting the entire RNAi ecosystem from discovery and comple
 x chemistry to clinical development and CMC\, this Summit provides an unp
 aralleled platform to tackle the field's most pressing challenge: deliver
 y beyond the liver. This is your unique opportunity to join 80+ senior le
 aders from pharma and biotech to gain the data-driven insights and high-v
 alue connections needed to overcome stability challenges\, de-risk clinic
 al translation\, and position your pipeline at the forefront of the next 
 therapeutic revolution.&nbsp\;\n\nURLs:Website:&nbsp\;https://go.evvnt.co
 m/3306289-0?pid=185Tickets:&nbsp\;https://go.evvnt.com/3306289-2?pid=185B
 rochure:&nbsp\;https://go.evvnt.com/3306289-4?pid=185\n\nPrices:Drug Deve
 loper Pricing - Conference + Workshop Day: USD 4197.00\,Drug Developer Pr
 icing - Conference Only: USD 2999.00\,Academic Pricing - Conference + Wor
 kshop Day: USD 3597.00\,Academic Pricing - Conference Only: USD 2599.00\,
 Service Provider Pricing - Conference + Workshop Day: USD 5097.00\,Servic
 e Provider Pricing - Conference Only: USD 3699.00\n\nSpeakers:&nbsp\;Andr
 ew Coles\, Senior Scientist\, Abbvie\, Muthiah Manoharan\, Senior Vice Pr
 esident\, Innovation Chemistry\, Alnylam Pharmaceuticals\, Paul Lawrence\
 , Executive Director - Bioscience Research\, Discovery and Scientific Com
 munications\, Biocogent\, Raj Reddy\, CEO\, Canary Cure\, David Jackson\,
  Chief Executive Officer\, Ceria Therapeutics\, Claire Zeng\, Founder\, C
 hief Technology Officer and Chief Executive Officer\, DoriNano\, Tere Wil
 liams\, Chief Executive Officer\, DUB Therapeutics\, Audrey Bernstein\, C
 SO\, DUB Therapeutics\, Yaniv Erlich\, Chief Executive Officer\, Eleven T
 herapeutics\, David Zebrowski\, Founder and Chief Executive Officer\, Gen
 Kardia\, Jonathan Hsu\, Chief Technology Officer\, Gensaic \, Uyanga &nbs
 p\;Tsedev\, Cheif Executive Officer\, Gensaic \, Lavi Errison\, CEO\, Gen
 saic\, Mauricio Garcia-Atance\, Program Director\, Hanson Wade\, Jinggang
  Ju\, Founder and Professor\, iNanoRNA Therapeutics\, Alfica Sehgal\, Chi
 ef Scientific Officer\, Judo Biosciences\, Joe Nabhan\, Chief Scientific 
 Officer\, K2B Therapeutics\, Anthony Saleh\, Chief Executive Officer\, mi
 Recule\, Yacoub Habib\, Chief Executive Officer\, Ophidion Inc\, James Ca
 rroll\, President and Chief Executive Officer\, RNA NanoBiotics\, Juhani 
 Lahdenpera\, Chief Operating Officer\, RNatives\, Weimin Wang\, Founder a
 nd Chief Executive Officer\, SanegeneBio\, Greta Garrido Hidalgo\, CEO an
 d Co-Founder\, Sebastian BioPharma\, Andre Fraley\, Partner\, Sunrise Bio
 ventures\, Zdravka Medarova\, Co-Founder and Chief Technology Officer\, T
 ransCode Therapeutics\, Julia Alterman\, Assistant Professor\, UMass Medi
 cal School\n\nCategory:&nbsp\;Conferences | Science\, Health and Medicine
  | Pharmaceuticals\n\nDate and Time:&nbsp\;27th January 2026 at 8:00 am t
 o 29th January 2026 at 4:30 pm\n\nVenue details:&nbsp\;Wyndham Boston Bea
 con Hill\, 5 Blossom Street\, Boston\, Massachusetts\, 02114\, United Sta
 tes\n
DTEND:20260129T163000
DTSTAMP:20260512T214303Z
DTSTART:20260127T080000
LOCATION:Wyndham Boston Beacon Hill\, 5\, Blossom Street\, Boston\, Massac
 husetts\, 02114\,
SEQUENCE:0
SUMMARY:Discover\, Develop and Selectively Deliver Highly Stable and Poten
 t RNAi Therapeutics for Targeted and Effective Gene Silencing in Oncology
 \, Rare\, C...
UID:8314af6e-fab6-4c14-a7eb-582be16e7dc2
END:VEVENT
END:VCALENDAR